References
- Brasil. Monitoramento de casos de dengue,febre de chikungunya e febre pelo vírus Zika até a semana epidemiológica 13,2016 [Monitoring of cases of dengue fever, chikungunya fever and Zika virus fever up to one epidemiological week 13,2016] .2016,47(18). Brasília: Ministério da Saúde. 2016.
- Brasil. Monitoramento de casos de dengue,febre de chikungunya e febre pelo vírus Zika até a semana epidemiológica 52,2017 [Monitoring of cases of dengue fever, chikungunya fever and Zika virus fever up to one epidemiological week 52,2017] .2017,49(2). Brasilia: Ministério da Saúde. 2017.
- Brasil. Monitoramento de casos de dengue,febre de chikungunya e febre pelo vírus Zika até a semana epidemiológica 10,2018 [Monitoring of cases of dengue fever, chikungunya fever and Zika virus fever up to one epidemiological week 10,2018].2018,49(14). Brasilia: Ministério da Saúde. 2018.
- Pan American Health Organization (PAHO)/World Health Organization (WHO) [internet]. Epidemiological Alert - Zika virus infection. 2015 [cited 2018 Apr 15]. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=30075&lang=en.
- Ali A, Wahid B, Rafique S, et al. Advances in research on Zika virus. Asian Pac J Trop Med. 2017;10(4):321–331.
- Faria NR, Azevedo R, Kraemer MUG, et al. Zika virus in the Americas: early epidemiological and genetic findings. Science. 2016;352:345–349.
- Dick GWA, Kitchen SF, Haddow AJ. Zika virus. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46:509–520.
- Wikan N, Smith RD. Zika virus: history of a newly emerging arbovirus. Lancet Infect Dis. 2016;16:e119–26.
- Brasil. Monitoramento integrado de alterações no crescimento e desenvolvimento relacionadas à infecção pelo vírus Zika e outras etiologias infecciosas, até a Semana Epidemiológica 52 de 2017 [Integrated monitoring of changes in growth and development related to Zika virus infection and other infectious etiologies until Epidemiological Week 52 of 2017].2018,49(6).Brasília: Ministério da saúde,2018.
- United Nations Development Programme [internet]. A socio-economic impact assessment of the Zika virus in Latin America and the Caribbean: with a focus on Brazil, Colombia and Suriname. New York, NY: UNDP; 2017 [cited 2018 Apr 15]. Available from http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/a-socio-economic-impact-assessment-of-the-zika-virus-in-latin-am.html
- Brasil. Ministério da Saúde. Programa Nacional de Controle da Dengue. Brasilia; 2002 [cited 2018 Apr 15]. Available from http://bvsms.saude.gov.br/bvs/publicacoes/pncd_2002.pdf
- World Health Organization [WHO]. Dengue vaccine: WHO position paper – July 2016. Wkly Epidemiol Rec. 2016;30:349–364.
- World Health Organization (WHO) [internet]. International travel and health - Chapter 6. New York, NY: WHO; 2017 [cited 2018 Oct 22]. Available from http://www.who.int/ith/ITH-Chapter6.pdf
- Baylor College of Medicine [internet]. Vaccine nation: 10 most important diseases without a licensed vaccine; 2013 Sep 12 [cited 2018 Oct 22]. Available from: https://blogs.bcm.edu/2013/09/03/vaccine-nation-10-most-important-diseases-without-a-licensed-vaccine/.
- Durbin AP. Vaccine development for Zika virus—timelines and strategies. Semin Reprod Med. 2016;34:299–304.
- Tebas P, Roberts CC, Muthumani K, et al.Safety and immunogenicity of an anti–Zika virus DNA vaccine — preliminary report. N Engl J Med. 2017.Oct4. 1-9. doi: 10.1056/NEJMoa1708120.
- Cohen J. Zika rewrites maternal immunization ethics. Science. 2017;357(6348):241.
- Modjarrad K, Lin L, George S, et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018;391:563–571.
- Wahid B, Ali A, Rafique S, et al. Current status of therapeutic and vaccine approaches against Zika virus. Eur J Intern Med. 2017;44:12–18.
- Brasil. Agência Nacional de Vigilância Sanitária. Resolução CMED n◦ 2, de 05 de Março de 2004. Brasília; 2004.
- Haab TC, McConnell KE. Valuing environmental and natural resources: the econometrics of non-market valuation. (New horizons in environmental economics). Cheltenham, UK; Northampton, MA, USA: E. Elgar Pub; 2002.
- Godói IP, Santos AS, Reis EA, et al. Consumer willingness to pay for dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil; implications for future pricing considerations. Front Pharmacol. 2017;8(FEB):1–9.
- Lee JS, Mongasale V, Lim JK, et al. A multi-country study of the household willingness-to-pay for Dengue vaccines: household surveys in Vietnam, Thailand, and Colombia. PLoS Negl Trop Dis. 2015;9(6).
- Ughasoro MD, Esangbedo DO, Tagbo BN, et al. Acceptability and willingness-to-pay for a hypothetical Ebola virus vaccine in Nigeria. PLos Negl Trop Dis. 2015;9(6):e0003838.
- Harapan H, Fajar JK, Kuch U. Dengue vaccine acceptance and willingness to pay. Hum Vaccin Immunother. 2017;13(4):786–790.
- Cameron MP, Newman PA, Roungprakhon S, et al. The marginal willingness-to-pay for attributes of a hypothetical HIV. Vaccine. 2013;31(36):3712–3717.
- Irwin KL, Jalloh MF, Corker J, et al. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: results of a national household survey. Vaccine. 2017;35(49):6915–6923.
- Huo X, Shi G, Li X, et al. Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone. Vaccine. 2016;24(15):1767–1772.
- Painter JE, von Fricken ME, Viana de O Mesquita S, et al. Willingness to pay for an Ebola vaccine during the 2014–2016 Ebola outbreak in West Africa: results from a U.S. National sample. Hum Vaccine Immunother. 2017;14(7):1665–1671.
- Nunn A, Brinkley-Rubinstein L, Rose J, et al. Latent class analysis of acceptability and willingness to pay for self-HIV testing in a United States urban neighbourhood with high rates of HIV infection. J Int AIDS Soc. 2017;20(1):21290.
- Whittington D, Matsui-Santana O, Freiberger JJ, et al. Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine. 2002;20(19):2585–2591.
- Olson D, Rick AM, Krager S, et al. Vaccine demand and willingness-to-pay for arbovirus vaccines: a cross-sectional survey in rural Guatemala. Pediatr Infect Dis J. 2018;37(11):1184–1189.
- Nguyen LH, Tran BX, Do CD, et al. Feasibility and willingness to pay for dengue vaccine in the threat of dengue fever outbreaks in Vietnam. Patient Prefer Adher. 2018;2018(12):1917–1926.
- Tian T, Wang D, Papamichael C, et al. HPV vaccination acceptability among men who have sex with men in Urumqi, China. Hum Vaccine Immunother. 2018. DOI:10.1080/21645515.2018.1520591.
- Brasil. Lei Nº 8.080, De 19 De Setembro De 1990. Brasilia; 1990. [cited 2018 April 22]. Available from: http://www.planalto.gov.br/ccivil_03/leis/L8080.htm.
- World Health Organization (WHO). Flawed but fair: Brazil’s health system reaches out to the poor [internet]. April 2008 [cited 2018 Mar 09]. Available from: http://www.who.int/bulletin/volumes/86/4/08-030408/en/.
- Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine. 2008;26:914–923.
- Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. United Kingdom: Oxford University Press; 2015.
- Guarulhos Web [internet]: rede particular oferece vacinas da febre amarela a partir de R$ 200,00 [Private clinics offers yellow fever vaccines starting at R $ 200,00]. 2018 Jan 08 [cited 2018 Oct 22]. Available from: http://www.guarulhosweb.com.br/noticia.php?nr=257528&t=Rede+particular+oferece+vacinas+da+febre+amarela+a+partir+de+R+20000.
- Atlas do Desenvolvimento Humano no Brasil (2016). Indicadores no Brasil.[internet] [cited 2017 Nov 16]. Available from: http://www.atlasbrasil.org.br/2013/pt/perfil_rm/belo-horizonte.
- Instituto Brasileiro de Geografia e Estatística [IBGE] (2014). Síntese de Indicadores Sociais: uma Análise das condições de vida da População Brasileira.[cited 2018 April 15]. Available from: http://biblioteca.ibge.gov.br/visualizacao/livros/liv91983.pdf.
- Johnston RJ, Boyle KJ, Adamowicz W, et al. Contemporary guidance for stated preference studies. J Ass Env Res Econ. 2017;4(2):319–405.
- OECD (Organisation for Economic Co-operation and Development) [Internet]. Exchange rates. 2017 [cited 2018 Oct 22]. Available from: https://data.oecd.org/conversion/exchange-rates.htm#indicator-chart
- Secretaria de Saude de Estado de Minas Gerais. Boletim Epidemiológico de monitoramento dos casos de dengue, chikungunya e zika vírus (26/02) [Epidemiological Bulletin on the monitoring of dengue, Chikungunya and Zika virus cases (02/26)]. Belo Horizonte 2018.
- Wong LP, Alias H, Hassan J, et al. Attitudes towards Zika screening and vaccination acceptability among pregnant women in Malaysia. Vaccine. 2017;35(43):5912–5917.
- Guo N, Zhang G, Zhu D. The effects of convenience and quality on the demand for vaccination: results from a discrete choice experiment. Vaccine. 2017;35(21):2848–2854.
- ANVISA (National Sanitary Surveillance Agency) [Internet]. Vacina contra dengue tem preço definido [Dengue vaccine has defined price]. 2016 Jul 25 [cited 2018 Oct 22]. Available from: http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/vacina-contra-dengue-tem-preco-definido/219201.
- Brasil. Minstério da Saúde. Portaria Nº 2.587 de 30 de Outubro de 2008. [cited 2018 March 13]. Available from: http://conitec.gov.br/images/Legislacao/Portaria2587_30.10.2008.pdf.
- Ministério da Saúde [Internet]. Orientações sobre Vacinação [Vaccination Guidance]. 2018 [cited 2018 Oct 22]. Available from: http://portalms.saude.gov.br/acoes-eprogramas/vacinacao/orientacoes-sobre-vacinacao.
- Brasil. Coeficiente de Adequação de Preços – CAP. Resolução nº 3, de 2 de março de 2011.Brasilia,2011.
- FINEP [Internet]. Finep vai investir R$ 230 milhões contra o Zika em 2016 [Finep will invest R$ 230 million to combat Zika in 2016]. 2016 Mar 24 [cited 2018 Mar 21]. Available from: http://www.finep.gov.br/noticias/todas-noticias/5223-finep-vai-investir-r-230-milhoes-contra-o-zika-em-2016.
- Prevenção e combate: Dengue,Chikungunya e Zika [Internet] : Ministério da Saúde. Saúde anuncia R$ 10 milhões para pesquisas contra Zika [Ministry of Health announces $ 10 million for research against Zika]. 2016 Jul 19 [cited 2018 Mar 21]. Available from: http://combateaedes.saude.gov.br/pt/noticias/401-ministerio-da-saude-anuncia-r-10-milhoes-para-pesquisas-contra-o-virus-Zika.
- Agencia Nacional de Saúde Complementar (ANS). Caderno de Informação da Saúde Suplementar: beneficiários, Operadoras e Planos [Supplementary Health Information Booklet: beneficiaries, Operators and Plans]. Rio de Janeiro: ANS; 2017.